After imploding three years ago, Aptinyx follows a painful setback with yet another PhII failure
More than three years after Aptinyx shares $APTX were squashed by a mid-stage setback for its lead drug, the biotech has unveiled the bottom-line results for a follow-up attempt to succeed where it first failed badly.
And it’s not pretty.
Pursuing a 50 mg dose of NYX-2925 in a study of 229 patients with advanced painful diabetic peripheral neuropathy — where researchers found some cause for encouragement in 2019 — did nothing to move the dial in comparison to a placebo. The biotech noted:
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 153,900+ biopharma pros reading Endpoints daily — and it's free.